PARP1 and breast carcinoma: Similarly, in the TNBC subgroup of the EMBRACA trial, which alsoenrolled patients with advanced breast cancer and a germline BRCAmutation, talazoparib improved PFS relative to single-agent chemotherapy.5 PARP is involved in the molecular events leading to cell recovery fromdeoxyribonucleic acid (DNA) damage.